Acadian Asset Management
CTKB icon

Acadian Asset Management’s Cytek Biosciences CTKB Stock Holding History

Acadian Asset Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.09M Buy
1,376,048
+977,060
+245% +$4.17M 0.01% 746
2026
Q1 		$1.74M Sell
398,988
-275,487
-41% -$1.3M ﹤0.01% 1000
2025
Q4 		$3.4M Buy
674,475
+108,902
+19% +$506K 0.01% 756
2025
Q3 		$1.96M Buy
565,573
+251,929
+80% +$946K ﹤0.01% 898
2025
Q2 		$1.06M Buy
313,644
+272,977
+671% +$910K ﹤0.01% 961
2025
Q1 		$162K Buy
+40,667
New +$211K ﹤0.01% 1288

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Acadian Asset Management's CTKB Position: Q2 2026 in Review

Acadian Asset Management increased its Cytek Biosciences (CTKB) stake by 245% in Q2 2026, buying an estimated $4.17M and bringing the position to 1,376,048 shares worth $6.09M. The position accounts for 0.01% of the portfolio, ranked #746.

Acadian Asset Management first reported a position in CTKB in Q1 2025 and has held it in 6 quarters since. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Acadian Asset Management held 1,376,048 shares of Cytek Biosciences worth $6.09M as of Q2 2026.
  • Acadian Asset Management bought 977,060 Cytek Biosciences shares in Q2 2026, an estimated $4.17M.
  • Cytek Biosciences made up 0.01% of Acadian Asset Management's portfolio in Q2 2026, its #746 holding.
  • Acadian Asset Management first reported a position in Cytek Biosciences in Q1 2025 and has held it in 6 quarters since.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.